PRGOHealthcare · Drug Manufacturers - Specialty & GenericThe 5 Wall Street analysts covering Perrigo Co. Plc hold a median 12-month price target of $16 — +17.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 76 of 100 as at 12 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Perrigo Co. Plc on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (98): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (24): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on PRGO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +17.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 Feb 2026 | Canaccord Genuity | Maintains | Buy | $20 → $17 |
| 15 Dec 2025 | JP Morgan | Maintains | Neutral | — |
| 6 Nov 2025 | Canaccord Genuity | Maintains | Buy | — |
| 6 Nov 2025 | JP Morgan | Downgrade | Neutral | — |
| 27 Oct 2025 | Jefferies | Maintains | Hold | — |
| 7 Aug 2025 | Canaccord Genuity | Maintains | Buy | — |
| 7 Aug 2025 | JP Morgan | Maintains | Overweight | — |
| 6 Jan 2025 | Piper Sandler | Downgrade | Neutral | — |
| 30 Sept 2024 | Canaccord Genuity | Maintains | Buy | — |
| 23 Sept 2024 | Jefferies | Downgrade | Hold | — |
| 11 July 2024 | Piper Sandler | Maintains | Overweight | — |
| 13 June 2024 | Piper Sandler | Maintains | Overweight | — |
| 12 Apr 2024 | Canaccord Genuity | Maintains | Buy | — |
| 8 Apr 2024 | Piper Sandler | Maintains | Overweight | — |
| 28 Feb 2024 | JP Morgan | Maintains | Overweight | — |
| 17 Nov 2023 | Piper Sandler | Initiates | Overweight | — |
| 9 Aug 2023 | JP Morgan | Maintains | Overweight | — |
| 7 Mar 2023 | Canaccord Genuity | Initiates | Buy | — |
| 6 Mar 2023 | Raymond James | Maintains | Outperform | — |
| 9 Nov 2022 | Raymond James | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PRGO appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Perrigo Co. Plc returned −35.2% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 1% of US stocks
Cheaper than 84% of US stocks
Cheaper than 80% of US stocks
Cheaper than 45% of US stocks
Higher than 22% of US stocks
Higher than 33% of US stocks
Higher than 35% of US stocks
Higher than 52% of US stocks
Higher than 11% of US stocks
Higher than 22% of US stocks
Higher than 58% of US stocks
Higher than 89% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Perrigo Co. Plc has a market value of $1.9B and an enterprise value of $5.0B.
Revenue in the twelve months to 30 June 2026: $4.1B. The latest quarter shrank 3.2% year on year.
Net income over the same four quarters: −$1.7B, a −41.9% net margin.
Diluted earnings per share, trailing twelve months: $−12.51.
Free cash flow in the twelve months to 30 June 2026: $119.3M.
Perrigo Co. Plc spent $159.9M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 2818.0×; forward P/E: 5.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 8.48%, paying out 10950% of earnings.
Perrigo Co. Plc employs 8,100 people — $512K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Perrigo Co. Plc — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Perrigo reported earnings 30 days ago, and its stock has risen 13.8% since that report. The article examines whether the gains can continue.
Why it matters — The stock's post-earnings movement and outlook are relevant to investors tracking PRGO's performance.
Perrigo Company plc announced that Interim President and CEO Albert Manzone and CFO Eduardo Bezerra are scheduled to participate in investor meetings at the Barclays Global Consumer Conference on September 10, 2026. The announcement was made via PRNewswire on August 27, 2026.
Why it matters — The company's participation in investor meetings at a major financial conference signals its engagement with the investment community and provides an opportunity for leadership to discuss the business.
Zacks Investment Research published a comparison of Perrigo (PRGO) and Neogen (NEOG), asking which of the two Medical - Products stocks is more attractive to value investors. The article weighs the two companies from a value-investing perspective.
Why it matters — PRGO watchers would care because the comparison directly evaluates Perrigo's attractiveness as a value stock against a peer in the same sector.
Zacks Investment Research discusses Perrigo stock in the context of its Rank system, which focuses on earnings estimates and estimate revisions, while also considering value, growth, and momentum trends to identify strong stock picks.
Why it matters — The item signals that Perrigo is being evaluated through Zacks' quantitative screening framework, which PRGO watchers may follow for potential rating implications.
The article notes that during market turbulence, many investors turn to dividend-yielding stocks, which are often companies with high free cash flows that reward shareholders with high dividend payouts. It highlights three health care stocks delivering high-dividend yields, including Perrigo.
Why it matters — A PRGO watcher would care because the item positions Perrigo among health care stocks that may appeal to income-focused investors seeking dividend yields during market uncertainty.
The 5 Wall Street analysts covering Perrigo Co. Plc have a median 12-month price target of $16, with estimates ranging from $14 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering Perrigo Co. Plc, 2 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Perrigo Co. Plc 76 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, Perrigo Co. Plc ranks 76 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (98 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +17.1% from the last close, and Ticker Nerd's factor model ranks Perrigo Co. Plc 76 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Perrigo Co. Plc publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PRGO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $20 over the next 12 months.
Perrigo Co. Plc returned -35.2% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Perrigo Company plc is a consumer health company that develops, manufactures, and markets self-care products and over-the-counter health and wellness solutions. Its portfolio spans products for everyday needs such as pain relief, digestive health, allergy care, cough and cold, nutrition, and infant care, serving consumers through branded and store-brand offerings.
The most recent item we track (Zacks Investment Research, 4 Sept 2026): "Perrigo (PRGO) Up 13.8% Since Last Earnings Report: Can It Continue?". Perrigo reported earnings 30 days ago, and its stock has risen 13.8% since that report. The article examines whether the gains can continue.
Perrigo Company plc is a consumer health company that develops, manufactures, and markets self-care products and over-the-counter health and wellness solutions. Its portfolio spans products for everyday needs such as pain relief, digestive health, allergy care, cough and cold, nutrition, and infant care, serving consumers through branded and store-brand offerings. The company also participates in selected prescription pharmaceutical and active ingredient businesses, giving it a broader presence across healthcare supply chains. Perrigo Company plc focuses on accessible, self-managed healthcare products that are distributed across the United States, Europe, and other international markets. Headquartered in Dublin, Ireland, Perrigo Company plc plays a significant role in the consumer health market by supplying large retailers, pharmacies, and healthcare channels with products designed for routine, non-prescription use.
CEO Mr. Albert Ange Manzone · 8,100 employees · Ireland · https://www.perrigo.com
